Pfizer's Xalkori lung-cancer drug performs well in another Phase III

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) Xalkori (Crizotinib) treatment met the main goal of a Phase III trial of untreated patients with a certain form of lung cancer by "significantly prolonging progression-free survival (PFS)" when compared with standard chemotherapy.

The study, called Profile 1014, is the second positive global Phase III test that evaluated Xalkori against chemotherapy.

Xalkori has already been authorized to treat previously treated patients. (PR)